Patient info Open main menu

Heparin Sodium Rovi 1 000 IU/ml solution for injection – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine strength:
1 000 IU/ml
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Heparin Sodium Rovi 1 000 IU/ml solution for injection

1. What Heparin Sodium ROVI 1,000 IU/mL is and what it is used for

The name of this medicine is Heparin Sodium ROVI 1,000 IU/mL solution for injection (referred to as ‘Heparin Sodium ROVI 1,000 IU/mL’ in this leaflet). Heparin sodium belongs to a group of medicines called anticoagulants. Heparin prevents blood clotting.

This medicine is used to treat and prevent:

  • Blood clots in leg veins (deep venous thrombosis)
  • Blood clots in the lung (pulmonary thromboembolism) as well as for:
  • The treatment of chest pains resulting from disease of the

    heart arteries (unstable angina pectoris)

  • The treatment of severe blockages affecting arteries in the legs

    (acute peripheral arterial occlusion)

  • The prevention of blood clots following a heart attack (mural

    thrombosis).

It is also used during heart and lung operations and during kidney dialysis.

2. What you need to know before you are given Heparin

Sodium ROVI 1,000 IU/mL solution for injection You should not be given Heparin Sodium ROVI 1,000 IU/mL solution for injection if you:

  • are allergic to heparin or any other ingredients of this medicine

    (listed in section 6),

  • are pregnant,
  • bleed or bruise easily,
  • have had severe skin problems resulting from previous heparin

    treatment,

  • are about to have surgery of the brain, spine or eye, a lumbar

    puncture or local anaesthetic nerve block or some other procedure where bleeding could be a problem.

Heparin Sodium ROVI 1,000 IU/mL solution for injection must not be given to premature or newborn babies or children up to 3 years of age.

Warnings and precautions

Talk to your doctor or nurse before receiving Heparin Sodium ROVI 1,000 IU/mL solution for injection. Particularly careful medical supervision is required if you:

  • are over 60 years of age,
  • have any condition which makes you likely to bleed more

    easily. If you are unsure ask your doctor or nurse,

  • are diabetic,
  • have high levels of potassium in the blood or if you take drugs

    that may increase the potassium level in your blood,

  • have kidney or liver disease. Your doctor may decide that a

    lower dose is necessary,

  • suffer from allergies or have previously had an allergic reaction

    to heparin.

Your doctor will check your blood if you receive treatment for longer than five days and may do other blood tests if you have major surgery.

Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).

Children

Heparin Sodium ROVI 1,000 IU/mL must not be given to premature or newborn babies or children under 3 years of age.

Other medicines and Heparin Sodium ROVI 1,000 IU/mL solution for injection

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Some medicines may affect the way heparin injection works. Taking some medicines at the same time as heparin may mean you may be likely to bleed more.

In particular, tell your doctor if you are taking any of the following medicines:

  • Aspirin or other non-steroidal anti-inflammatory drugs (e.g

    diclofenac or ibuprofen),

  • Medicines which may interfere with the proper clotting of the blood (e.g. dipyridamole, epoprostenol, clopidogrel or

    streptokinase),

  • Medicines that may increase the potassium level in your blood,
  • Glyceryl trinitrate (for heart disease).

If you need one of the above medicines your doctor may decide to alter the dose of heparin injection or the other medication. If you have any doubts about whether this medicine should be administered then discuss things more fully with your doctor or nurse before Heparin Sodium ROVI 1,000 IU/mL is given.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before receiving this medicine. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).

You should not be given Heparin Sodium ROVI 1,000 IU/mL if you are pregnant.

Driving and using machines

Heparin Sodium ROVI 1,000 IU/mL solution for injection has not been reported to affect the ability to drive or operate machines.

Heparin Sodium ROVI 1,000 IU/mL contains benzyl alcohol

This medicine contains 10 mg/mL of benzyl alcohol in each mL. Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called “gasping syndrome”) in young children.

Heparin Sodium ROVI 1,000 IU/mL contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

3. How Heparin Sodium ROVI 1,000 IU/mL solution for injection is given

Your doctor or nurse will inject your dose of heparin into a vein either all at once or over a longer period of time (usually via a drip). Alternatively they may inject your heparin underneath your skin.

The amount injected all at once into a vein should not be greater than 15 mL.

You may need to have blood tests if you are receiving higher doses of heparin to check on the effects of your heparin treatment.

Heparin injection must not be given to premature or newborn babies.

You may require a lower dose if you have kidney or liver disease.

To prevent blood clots in leg veins (deep vein thrombosis) and blood clots in the lung (pulmonary embolism)

Adults

The usual dose of heparin injection in adults is 5,000 units injected under the skin 2 hours before your operation, followed by:

  • 5,000 units injected under the skin every 8-12 hours, for 7-10

    days or until you are fully able to move about.

Elderly

Lower doses may be used in the elderly. You may need to have blood tests if you are elderly, to check on the effects of your heparin treatment.

Children

No specific doses are recommended.

To treat blood clots in leg veins (deep vein thrombosis) and blood clots in the lung (pulmonary embolism) Adults

The usual dose in adults is 5,000 units injected into a vein. This is followed by:

  • 1,000-2,000 units/hour injected slowly into a vein or
  • 5,000-10,000 units 4-hourly injected all at once into a vein. Elderly

Lower doses may be used in the elderly.

Small adults and children

Small adults and children will be given 50 units/kg bodyweight injected into a vein followed by:

  • 15-25 units/kg bodyweight/hour injected slowly into a vein or
  • 100 units/kg bodyweight 4-hourly injected all at once into a

    vein.

To treat chest pains (unstable angina pectoris) and severe blood clots in the arteries (acute peripheral arterial occlusion)

Adults

The usual dose in adults is 5,000 units injected into a vein. This is followed by:

  • 1,000-2,000 units/hour injected slowly into a vein or
  • 5,000-10,000 units 4-hourly injected all at once into a vein. Elderly

Lower doses maybe used in the elderly.

Small adults and children

Small adults and children will be given 50 units/kg body weight injected into a vein followed by:

  • 15-25 units/kg bodyweight/hour injected slowly into a vein or
  • 100 units/kg bodyweight 4-hourly injected all at once into a

    vein.

You will have blood tests every day to check the effects of your heparin.

To prevent a blood clot in the heart following a heart attack

Adults

The usual dose for adults is 12,500 units 12-hourly injected under the skin for at least 10 days.

Elderly

A lower dose may be needed.

During heart and lung surgery

Adults

Initially you will be given 300 units/kg body weight. This will be changed according to the results of your blood tests.

During kidney dialysis

Adults

Initially you will be given 1,000-5,000 units. This will be changed according to the results of your blood tests.

If you think you have been given too much Heparin Sodium ROVI 1,000 IU/mL

Your doctor will decide which dose is best for you.

Too much heparin can cause bleeding. Slight bleeding can be stopped by stopping your heparin treatment. However, if you have more severe bleeding you may need blood tests and an injection of a medicine called protamine sulphate.

If you think too much medicine has been given to you, contact your doctor or nurse.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.

Important side effects to look out for (frequency not stated):

Severe allergic reactions

Heparin can cause a rare severe allergic reaction with wheezing, difficulty breathing, a blue tinge to the lips, fever, chills, swelling of the eyes and lips and shock.

If you think you are having a severe allergic reaction you must stop receiving heparin and tell your doctor or nurse immediately.

Bleeding and bruising

Signs that you are bleeding more easily include:

  • unusual bruising or purple spots on your skin,
  • unusual bleeding from your gums,
  • unusual nose bleeds,
  • blood in your urine (which may cause this to go dark),
  • black, tarry-looking stools,
  • bleeding that will not stop from any operation site or other injury.

    If you are concerned about unusual bleeding you must tell your doctor or nurse immediately as you may need to stop your heparin treatment.

    Other side effects (frequency not stated) include:

    • red lumps or red, itchy patches like eczema often develop 3-21 days after the start of heparin treatment, where injections have been given under the skin,
    • irregularly shaped, red skin lesions with blisters,
    • sloughing of skin may occur around the injection site,
    • persistent erection of the penis,
    • abnormal results for blood tests that report on how the liver is working,
    • high level of blood fats after stopping heparin,
    • high or low potassium levels. If affected you may feel tired and weak.

If heparin injection is given over many months, then the following may occur:

  • hair loss,
  • thinning of the bones (osteoporosis).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Heparin Sodium ROVI 1,000 IU/mL solution for injection

Keep this medicine out of the sight and reach of children.

Your doctor or nurse will usually be responsible for storing and preparing injection before use and for checking that the vials have not passed their expiry date stated on the carton and the label. This medicine must not be used after the expiry date which is stated on the carton and the label. The expiry date refers to the last day of that month.

Heparin injection should not be given if it shows signs of deterioration such as discolouration.

This medicinal product does not require any special storage conditions.

After opening the vial, immediately administer the product.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Heparin Sodium ROVI 1,000 IU/mL solution for injection contains

  • The active substance is heparin sodium.
  • Each vial with 5 mL solution for injection contains 5,000 units of heparin sodium.
  • The other ingredients are sodium chloride, benzyl alcohol (10 mg/mL), sodium hydroxide and water for injections.

What Heparin Sodium ROVI 1,000 IU/mL solution for injection looks like and contents of the pack

This product comes as a colourless, clear solution with no visible particles.

This product is available in packs of 10 vials of 5 mL solution for injection.

Marketing Authorisation Holder and Manufacturer:

Marketing Authorization Holder

Laboratorios Farmacéuticos ROVI, S.A.

Julián Camarillo, 35

28037 – Madrid. Spain

Manufacturer

ROVI PHARMA INDUSTRIAL SERVICES, S.A.

Julián Camarillo, 35

28037-Madrid. Spain

UK distributor (Great Britain)

ROVI Biotech Limited

One Emfield Park, Office No. 2.06

Bromley BR1 1LU. United Kingdom

This leaflet was last revised in October 2025.

Package leaflet: information for the user

Heparin Sodium ROVI 1,000 IU/mL solution for injection

heparin sodium

The following information is intended for healthcare professionals only:

How to prepare and administer

By continuous intravenous infusion or by intermittent intravenous injection, or by subcutaneous injection. The intravenous injection volume of heparin injection should not exceed 15 mL. As the effects of heparin are short-lived, administration by intravenous infusion or subcutaneous injection is preferable to intermittent intravenous injections.

Heparin sodium may be administered intravenously (in continuous infusion or bolus administration) or subcutaneously. Do not administer by the intramuscular route, due to the risk of developing local haematoma.

The heparin dose should be individualised and adjusted to clotting times.

The recommended dose varies according to the different indications, as follows:

Prophylaxis of deep vein thrombosis and pulmonary embolism Adults:

2 hours pre-operatively: 5,000 units subcutaneously followed by: 5,000 units subcutaneously every 8-12 hours, for 7-10 days or until the patient is fully ambulant

No laboratory monitoring should be necessary during low dose heparin prophylaxis. If monitoring is considered desirable, anti-Xa assays should be used as the activated partial thromboplastin time (APTT) is not significantly prolonged.

Elderly:

Dosage reduction and monitoring of APTT may be advisable.

Paediatric population:

No dosage recommendations.

Treatment of deep vein thrombosis and pulmonary embolism Adults:

Loading dose: 5,000 units intravenously (10,000 units may be required in severe pulmonary embolism) Maintenance: 1,000-2,000 units/hour by intravenous infusion, or 5,000-10,000 units 4-hourly by intravenous injection

Elderly:

Dosage reduction may be advisable.

Children and small adults:

Loading dose: 50 units/kg intravenously

Maintenance: 15-25 units/kg/hour by intravenous infusion, or 100 units/kg 4-hourly by intravenous injection

The following information is intended for healthcare professionals only:

Treatment of unstable angina pectoris and acute peripheral arterial occlusion

Adults:

Loading dose: 5,000 units intravenously

Maintenance: 1,000-2,000 units/hour by intravenous infusion, or 5,000-10,000 units 4-hourly by intravenous injection

Elderly:

Dosage reduction may be advisable.

Children and small adults:

Loading dose: 50 units/kg intravenously

Maintenance: 15-25 units/kg/hour by intravenous infusion, or 100 units/kg 4-hourly by intravenous injection Daily laboratory monitoring (ideally at the same time each day, starting 4-6 hours after initiation of treatment) is essential during full-dose heparin treatment, with adjustment of dosage to maintain an APTT value 1.5-2.5 x midpoint of normal range or control value.

Prophylaxis of mural thrombosis following myocardial infarction Adults:

12,500 units 12-hourly subcutaneously for at least 10 days.

Elderly:

Dosage reduction may be advisable.

Prevention of thrombosis in extracorporeal circulation circuit during heart surgery and haemodialysis

Heart surgery: It is recommended to heparinise the patient with 300 units/kg, adjusted thereafter to maintain the activated clotting time (ACT) in the range 400-500 seconds.

Haemodialysis and haemofiltration:

Initially: 1,000-5,000 units

Maintenance: 1,000-2,000 units/hour, adjusted to maintain clotting time > 40 minutes

Heparin resistance

Patients with altered heparin responsiveness or heparin resistance may require disproportionately higher doses of heparin to achieve the desired effect.

Renal and hepatic impairment:

A lower dose may be necessary. It is recommended to adjust the dose in accordance with the weight and the required APTT levels.

REV 13 Heparin Sodium ROVI 1.000

P. 294 C

Fonts

Programs

Helvetica

Adobe Illustrator CS5

Heparin Sodium ROVI 1.000

Leaflet

210x440 mm

FO- MANUAL-029 Rev.A Product

Tipe

Tech. Drawing

26/09/2023

10/04/2024 Requested by

Application date

Performed and revised

Answer date

Notes

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 15406/0016

Last revision stated in the text: October 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Heparin Sodium Rovi 1 000 IU/ml solution for injection

Active substance Heparin
Strength 1 000 IU/ml
Pharmaceutical form Colourless or slightly yellowish, clear solution, free of visible particles.
Excipients Sodium chloride, Benzyl alcohol, Sodium hydroxide (for pH adjustment), Water for injections
Shelf life 3 years.
Once the vial has been opened, administer the product immediately.
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Antithrombotic agents
  1. B Blood and blood forming organ drugs
    1. B01 Antithrombotic agents
      1. B01A Antithrombotic agents
        1. B01AB Heparin group antithrombotic drugs
          1. B01AB01 heparin
Marketing authorisation PL 15406/0016 (first authorised 7 January 2022)
Marketing authorisation holder Laboratorios Farmacéuticos ROVI S.A

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.